Don Nguyen, MD
Ophthalmology · Edmond, OKNPI 1588957146
Payments from drug & device makers
Across 556 payments — averaging $65.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$16K
- AbbVie$5K
- Ivantis, Inc$4K
- Leica Microsystems Inc.$3K
- Alcon$3K
- Harrow Eye, LLC$683
- plus $5K from 23 others
Across 6 payments — averaging $6348.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- NEW World Medical,inc.$35K
- Alcon Research LLC$3K
What the payments were for
- Consulting fees$7,78621%
- Speaking & faculty fees$11,60032%
- Food & beverage$16,95147%
- Education$150%
- Gifts$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 61 | $16,075 |
| AbbVie(2 entities) | 214 | $5,314 |
| Ivantis, Inc | 3 | $4,137 |
| Leica Microsystems Inc. | 2 | $2,935 |
| Alcon | 107 | $2,525 |
| Harrow Eye, LLC | 19 | $683 |
| Sight Sciences, Inc. | 24 | $600 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $458 |
| The Cameron-ehlen Group, Inc. | 5 | $389 |
| Novartis | 19 | $358 |
| Aerie Pharmaceuticals, Inc. | 17 | $324 |
| Glaukos Corporation | 8 | $322 |
| Bausch & Lomb Americas Inc. | 14 | $300 |
| Rxsight Inc | 7 | $299 |
| Sun Pharmaceutical Industries Inc. | 8 | $244 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $238 |
| Tarsus Pharmaceuticals, Inc. | 1 | $188 |
| Ocular Therapeutix, Inc. | 5 | $162 |
| Nova Eye, Inc. | 1 | $148 |
| Biotissue Holdings Inc. | 1 | $134 |
| Optos, Inc. | 1 | $108 |
| Carl Zeiss Meditec USA, Inc. | 2 | $104 |
| Eyevance Pharmaceuticals LLC | 5 | $102 |
| Thea Pharma Inc. | 4 | $94 |
| Shire North American Group Inc | 4 | $78 |
| ANI Pharmaceuticals, Inc. | 2 | $63 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kahook Dual Blade$5,222
- Ahmed Glaucoma Valve$5,222
- Streamline Surgical System$3,555
- SURGICAL MICROSCOPES$2,886
- Hydrus$2,783
- Hydrus Microstent$1,778
- Clearpath$1,668
- Streamline$1,668
- Via360$1,566
- XEN GLAUCOMA TREATMENT SYSTEM$786
- DURYSTA$570
- LUMIGAN$239
- VEVYE$217
- PANORAMIC OPHTHALMOSCOPE$216
- XDEMVY$188
- CATALYS SYSTEM$145
- OMNI(R) SURGICAL SYSTEM (US)$131
- iStent$125
- KXL System$125
- Photrexa$125
How this compares
$36,442 in reported general payments places this provider in the 95th percentile of 183 ophthalmology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 223 | $97,421 |
| VyzultaLatanoprostene Bunod | 131 | $52,345 |
| CombiganBrimonidine Tartrate/Timolol | 109 | $31,048 |
| RocklatanNetarsudil Mesylat/Latanoprost | 84 | $29,323 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 112 | $25,658 |
| RhopressaNetarsudil Mesylate | 51 | $20,891 |
| Alphagan PBrimonidine Tartrate | 33 | $13,626 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 110 | $12,978 |
| RestasisCyclosporine | 18 | $11,929 |
| FlarexFluorometholone Acetate | 87 | $10,870 |
| MoxifloxacinMoxifloxacin Hcl | 327 | $9,411 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 588 | $8,409 |
| Prednisolone Acetate | 257 | $8,063 |
| Latanoprost | 573 | $7,200 |
| IyuzehLatanoprost/Pf | 15 | $6,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $5,314 | $154,024383 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $300 | $52,345131 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $324 | $50,214135 claims |
| AlconSimbrinza | $2,525 | $25,658112 claims |
| Eyevance Pharmaceuticals LLCFlarex | $102 | $10,87087 claims |
| Thea Pharma Inc.Iyuzeh | $94 | $6,89415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 183 ophthalmology providers in Oklahoma.
Other ophthalmology in Edmond
- Bradley BrittonEdmond$25K
- Jeffrey ShaverEdmond$11K
- Whitney PotterEdmond$10K
- Michael HogueEdmond$6K
- Vincent VenincasaEdmond$5K
- Jared JacksonEdmond$3K
- Brian MorganEdmond$3K
- Justin ParschauerTulsa$885K
- Ronald RebenitschOklahoma City$141K
- Mark WeissTulsa$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.